You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 12,194,022

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,194,022

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
Assignee:	Acacia Pharma Ltd
Application Number:	US18/095,612
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,194,022
Patent Claims:	1. A method for the prevention of post-operative nausea and vomiting (PONV) in a human in need of such prevention comprising intravenously administering to the human an anti-emetic, wherein the anti-emetic is S-amisulpride at a dose of 2.5 mg. 2. The method according to claim 1, wherein the subject is also administered an emetogenic agent. 3. The method according to claim 2, wherein the emetogenic agent is an opiate. 4. The method according to claim 2, wherein the emetogenic agent is morphine. 5. The method according to claim 1, wherein the human is also administered an anesthetic. 6. The method according to claim 1, wherein the S-amisulpride is administered in combination with another anti-emetic drug. 7. The method according to claim 6, wherein the another anti-emetic drug is a 5HT3 antagonist, an NK1 antagonist, or a steroid. 8. The method of claim 7, wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant. 9. The method according to claim 7, wherein the 5HT3 antagonist is ondansetron. 10. The method of claim 1, wherein the S-amisulpride is administered in the form of a pharmaceutical composition comprising S-amisulpride, citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride. 11. The method of claim 10, wherein the pharmaceutical composition comprises 0.25% w/v amisulpride. 12. The method of claim 10, wherein the pharmaceutical composition comprises 0.25% w/v amisulpride, 0.935% w/v citric acid monohydrate, 1.632% w/v trisodium citrate dihydrate, and 0.18% w/v sodium chloride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.